{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-060556","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2026-05-22T20:05:31+00:00","discovered_at":"2026-05-22T20:07:00.267305+00:00","generated_at":"2026-05-22T20:08:01.459469+00:00","sec_items":["3.01"],"event_type":"other","sentiment":"negative","materiality_score":0.6,"confidence":"high","headline":"Envoy Medical receives Nasdaq extension to November 16, 2026 to cure bid price deficiency","bullets":["Company received Nasdaq notice granting additional 180-day period until November 16, 2026 to meet $1.00 minimum bid price.","Initial compliance period ended May 18, 2026; company had not yet satisfied the bid price requirement.","Extension based on meeting other listing requirements and written intent to cure via reverse stock split if needed.","If not cured by new deadline, common stock may be delisted from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060556","json":"https://secwatch.observer/filing/0001213900-26-060556.json","markdown":"https://secwatch.observer/filing/0001213900-26-060556.md","text":"https://secwatch.observer/filing/0001213900-26-060556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026060556/0001213900-26-060556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026060556/ea0292043-8k_envoy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T20:08:01.459469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6bfe89869c8cd123c9ece33912fd4738be76fa9","claim":"Envoy Medical, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"On May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an additional 180 day period, until November 16, 2026, to meet the Bid Price Requirement","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026060556/0001213900-26-060556-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}